AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05317832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WI program
Description: This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
Study NCT05317832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WI Program Reminder
Description: Participants will be provided with reminders to use the WI program
Study NCT05317832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WI Program Reminder
Description: Participants will be provided with reminders to use the WI program
Study NCT05317832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JITAI Goal Setting
Description: Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
Study NCT05317832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JITAI physical activity message
Description: Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
Study NCT05317832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification EMA
Description: Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
Study NCT05317832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End of day EMA
Description: Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
Study NCT05317832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wake up time EMA
Description: Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
Study NCT05317832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weekly PA Information
Description: Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
Study NCT05317832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly PA Information
Description: Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
Study NCT05317832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily PA Information
Description: Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
Study NCT04934397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Infant Formula
Description: Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
Study NCT06040060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
Study NCT06040060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
Study NCT05830591 — intervention group
Intervention type: OTHER
Intervention: Characterization of the microbiome in oral and fecal samples
Description: The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
Study NCT06131177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Protein supplement
Study NCT04851834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-301
Description: Oral hypomethylating agent
Study NCT04851834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Standard of care for ovarian and bladder cancer
Study NCT04851834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care for high-grade glioma
Study NCT05705596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 10% sucrose corresponding to a regular soft drink
Study NCT05705596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hesperetin
Description: increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
Study NCT05564390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO
Study NCT06400342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR-explant
Description: Surgical explantation of failed THV followed by surgical aortic valve replacement and any other cardiac surgeries deemed necessary.
Study NCT06400342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Redo-TAVR
Description: Repeat transcatheter aortic valve implantation within a failed THV.
Study NCT05193786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different level of PEEP
Description: Different level of PEEP (low versus high) was applied in noninvasive ventilation.
Study NCT05193786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Different level of PEEP
Description: Different level of PEEP (low versus high) was applied in noninvasive ventilation.
Study NCT05741164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05741164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05741164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05741164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05741164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Given PO
Study NCT05741164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05406440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
Study NCT05406440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.
Study NCT05248646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibeprenlimab 400 mg
Description: Sibeprenlimab 400 mg s.c. q 4 weeks
Study NCT05248646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. q 4 weeks
Study NCT06009627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcelli、Exemestane、Gosserine
Description: Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration
Study NCT06009627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
Description: Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat
Study NCT05368311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary recommendations including protein enriched bars
Description: Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
Study NCT05083949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 12.5mg empagliflozin/850mg metformin
Description: empagliflozin/metformin
Study NCT05368311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary recommendations without protein enriched bars
Description: Volunteers allocated in the experimental group will receive dietary recommendations.
Study NCT05095571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EH301 (Nicotinamide Riboside/Pterostilbene)
Description: For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
Study NCT04565925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Sildenafil 20mg TID for 4 weeks
Study NCT04565925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (Lactose) TID for 4 weeks
Study NCT05083949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: empagliflozin 10mg (R1)
Study NCT05083949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glifage®
Description: Glifage® 850mg (R2)
Study NCT05426967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active rTMS
Study NCT05426967 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham comparator to active rTMS
Study NCT05911165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No surgical coaching
Description: During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
Study NCT05911165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical coaching
Description: Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
Study NCT05480995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone PET / MRI
Description: Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
Study NCT06414798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ABBV-1088
Description: • Oral Capsule
Study NCT06414798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo for ABBV-1088
Description: • Oral Capsule
Study NCT05257629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)
Description: Varenicline and nicotine e-cigarettes plus counseling
Study NCT05257629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Varenicline Plus Counseling
Description: Varenicline plus counseling
Study NCT06218641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CP - conventional protocol
Description: All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner.
Study NCT06218641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DP - delayed protocol
Description: All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner.
Study NCT04784247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20mg daily (two 10mg lenvatinib capsules) taken orally
Study NCT04784247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
Study NCT05225506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
Study NCT05750485 — intervention group
Intervention type: OTHER
Intervention: Pupilometric evaluation
Description: Pupilometric evaluation under procedural sedation with propofol
Study NCT06074419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occulus quest 2 virtual reality glasses
Description: Patients will be shown nature videos via the specified virtual reality connection.
Study NCT05987657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Salivary and blood progesterone dosage
Description: Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval.
Study NCT06273241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food intake
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .
Study NCT06273241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: food intake
Description: A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .
Study NCT04889755 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SibACCESS
Description: The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
Study NCT05212376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days.
Study NCT05135429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bathing
Description: The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
Study NCT04869332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: three cancellous screws
Description: All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
Study NCT04869332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: four cancellous screws
Description: All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
Study NCT05251090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: 50 international units (IU)/kg, a single dose.
Study NCT05251090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW107
Description: 50 IU/kg, a single dose.
Study NCT06062511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ESIT12 D
Description: ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
Study NCT06062511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ESIT12 4D
Description: ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
Study NCT06062511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
Study NCT06095583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tifcemalimab injection
Description: 200mg once every 3weeks
Study NCT06095583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab injection
Description: 240mg once every 3 weeks
Study NCT06095583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tifcemalimab
Description: every 3weeks
Study NCT06095583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tifcemalimab
Description: every 3weeks
Study NCT06095583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for toripalimab
Description: every 3weeks
Study NCT04890561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant oral tablets.
Study NCT04955509 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: conventional MRI and diffusion MRI